免疫参数与啮齿动物和非人类灵长类动物对埃博拉病毒感染的保护作用相关。
Immune parameters correlate with protection against ebola virus infection in rodents and nonhuman primates.
机构信息
Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba R3E 3R2, Canada.
出版信息
Sci Transl Med. 2012 Oct 31;4(158):158ra146. doi: 10.1126/scitranslmed.3004582.
Abstract
Ebola virus causes severe hemorrhagic fever in susceptible hosts. Currently, no licensed vaccines or treatments are available; however, several experimental vaccines have been successful in protecting rodents and nonhuman primates (NHPs) from the lethal Zaire ebolavirus (ZEBOV) infection. The objective of this study was to evaluate immune responses correlating with survival in these animals after lethal challenge with ZEBOV. Knockout mice with impaired ability to generate normal T and/or B cell responses were vaccinated and challenged with ZEBOV. Vaccine-induced protection in mice was mainly mediated by B cells and CD4(+) T cells. Vaccinated, outbred guinea pigs and NHPs demonstrated the highest correlation between survival and levels of total immunoglobulin G (IgG) specific to the ZEBOV glycoprotein (ZGP). These results highlight the relevance of total ZGP-specific IgG levels as a meaningful correlate of protection against ZEBOV exposure.
摘要
埃博拉病毒可导致易感宿主发生严重的出血热。目前，尚无获得许可的疫苗或治疗方法可用；然而，一些实验性疫苗已成功地保护啮齿动物和非人灵长类动物（NHPs）免受致命的扎伊尔埃博拉病毒（ZEBOV）感染。本研究的目的是评估在这些动物中与在致命的 ZEBOV 攻击后的存活相关的免疫反应。用无法产生正常 T 和/或 B 细胞反应的能力受损的基因敲除小鼠进行疫苗接种和 ZEBOV 攻击。疫苗诱导的小鼠保护主要由 B 细胞和 CD4(+)T 细胞介导。接种疫苗的、杂交的豚鼠和 NHPs 显示出存活与针对 ZEBOV 糖蛋白（ZGP）的总免疫球蛋白 G（IgG）特异性之间的最高相关性。这些结果突出了总 ZGP 特异性 IgG 水平作为针对 ZEBOV 暴露的保护的有意义的相关性。
相似文献
1
Immune parameters correlate with protection against ebola virus infection in rodents and nonhuman primates.免疫参数与啮齿动物和非人类灵长类动物对埃博拉病毒感染的保护作用相关。
Sci Transl Med. 2012 Oct 31;4(158):158ra146. doi: 10.1126/scitranslmed.3004582.
2
Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates.抗体对于 rVSV/ZEBOV-GP 介导的非人类灵长类动物抵抗致死性埃博拉病毒攻击的保护是必要的。
Proc Natl Acad Sci U S A. 2013 Jan 29;110(5):1893-8. doi: 10.1073/pnas.1209591110. Epub 2013 Jan 14.
3
Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus.单次注射疫苗可保护非人灵长类动物免受马尔堡病毒和三种埃博拉病毒的感染。
J Virol. 2009 Jul;83(14):7296-304. doi: 10.1128/JVI.00561-09. Epub 2009 Apr 22.
4
Enhanced protection against Ebola virus mediated by an improved adenovirus-based vaccine.一种改进的基于腺病毒的疫苗介导的对埃博拉病毒的增强保护作用。
PLoS One. 2009;4(4):e5308. doi: 10.1371/journal.pone.0005308. Epub 2009 Apr 23.
5
Modeling the Disease Course of Zaire ebolavirus Infection in the Outbred Guinea Pig.对远交系豚鼠体内扎伊尔埃博拉病毒感染病程进行建模。
J Infect Dis. 2015 Oct 1;212 Suppl 2:S305-15. doi: 10.1093/infdis/jiv237. Epub 2015 Jun 2.
6
rVSVΔG-ZEBOV-GP Vaccine Is Highly Immunogenic and Efficacious Across a Wide Dose Range in a Nonhuman Primate EBOV Challenge Model.rVSVΔG-ZEBOV-GP疫苗在非人灵长类埃博拉病毒攻击模型中的广泛剂量范围内具有高度免疫原性且有效。
Viruses. 2025 Feb 28;17(3):341. doi: 10.3390/v17030341.
7
Ebolavirus Glycoprotein Fc Fusion Protein Protects Guinea Pigs against Lethal Challenge.埃博拉病毒糖蛋白Fc融合蛋白可保护豚鼠免受致死性攻击。
PLoS One. 2016 Sep 13;11(9):e0162446. doi: 10.1371/journal.pone.0162446. eCollection 2016.
8
Vesicular stomatitis virus-based vaccines protect nonhuman primates against Bundibugyo ebolavirus.基于水疱性口炎病毒的疫苗可保护非人灵长类动物免受本迪布焦埃博拉病毒感染。
PLoS Negl Trop Dis. 2013 Dec 19;7(12):e2600. doi: 10.1371/journal.pntd.0002600. eCollection 2013.
9
Immunopathogenesis of severe acute respiratory disease in Zaire ebolavirus-infected pigs.扎伊尔埃博拉病毒感染猪的严重急性呼吸道疾病的免疫发病机制。
PLoS One. 2013 Apr 23;8(4):e61904. doi: 10.1371/journal.pone.0061904. Print 2013.
10
Durability of Immunogenicity and Protection of rVSV∆G-ZEBOV-GP Vaccine in a Nonhuman Primate EBOV Challenge Model.rVSV∆G-ZEBOV-GP疫苗在非人灵长类埃博拉病毒攻击模型中的免疫原性持久性及保护作用
Viruses. 2025 Feb 28;17(3):342. doi: 10.3390/v17030342.
引用本文的文献
1
Plasmonic Nanoceria: A Plasmon-Enhanced Nanohybrid for Rapid and Sensitive Detection of Ebola Glycoprotein.等离子体纳米氧化铈：一种用于快速灵敏检测埃博拉糖蛋白的等离子体增强纳米杂化物。
ACS Appl Nano Mater. 2025 Apr 30;8(18):9604-9612. doi: 10.1021/acsanm.5c01649. eCollection 2025 May 9.
2
A Phase 1 randomized trial of homologous and heterologous filovirus vaccines with a late booster dose.一项采用晚期加强剂量的同源和异源丝状病毒疫苗的1期随机试验。
NPJ Vaccines. 2024 Dec 23;9(1):255. doi: 10.1038/s41541-024-01042-4.
3
Long-term cellular immunity of vaccines for Zaire Ebola Virus Diseases.扎伊尔埃博拉病毒病疫苗的长期细胞免疫。
Nat Commun. 2024 Sep 3;15(1):7666. doi: 10.1038/s41467-024-51453-z.
4
Ebola Virus Disease Vaccines: Development, Current Perspectives & Challenges.埃博拉病毒病疫苗：研发、当前观点与挑战
Vaccines (Basel). 2023 Jan 26;11(2):268. doi: 10.3390/vaccines11020268.
5
Non-human primate to human immunobridging demonstrates a protective effect of Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola.非人灵长类动物到人类的免疫桥接研究表明，Ad26.ZEBOV-MVA-BN-Filo疫苗对埃博拉具有保护作用。
NPJ Vaccines. 2022 Nov 30;7(1):156. doi: 10.1038/s41541-022-00564-z.
6
Bridging Animal and Human Data in Pursuit of Vaccine Licensure.为追求疫苗许可而搭建动物与人类数据的桥梁。
Vaccines (Basel). 2022 Aug 25;10(9):1384. doi: 10.3390/vaccines10091384.
7
Immune Correlates of Protection from Filovirus Efficacy Studies in Non-Human Primates.非人灵长类动物中丝状病毒疗效研究的保护免疫相关因素
Vaccines (Basel). 2022 Aug 18;10(8):1338. doi: 10.3390/vaccines10081338.
8
Transcriptomic signatures induced by the Ebola virus vaccine rVSVΔG-ZEBOV-GP in adult cohorts in Europe, Africa, and North America: a molecular biomarker study.在欧洲、非洲和北美洲的成年人群中，埃博拉病毒疫苗 rVSVΔG-ZEBOV-GP 诱导的转录组特征：分子生物标志物研究。
Lancet Microbe. 2022 Feb;3(2):e113-e123. doi: 10.1016/S2666-5247(21)00235-4. Epub 2021 Dec 6.
9
Role of Key Infectivity Parameters in the Transmission of Ebola Virus Makona in Macaques.关键感染参数在猕猴中传播埃博拉病毒马科纳中的作用。
J Infect Dis. 2022 Sep 4;226(4):616-624. doi: 10.1093/infdis/jiab478.
10
Filovirus Neutralising Antibodies: Mechanisms of Action and Therapeutic Application.丝状病毒中和抗体：作用机制与治疗应用
Pathogens. 2021 Sep 16;10(9):1201. doi: 10.3390/pathogens10091201.
本文引用的文献
1
Successful treatment of ebola virus-infected cynomolgus macaques with monoclonal antibodies.用单克隆抗体成功治疗感染埃博拉病毒的食蟹猴。
Sci Transl Med. 2012 Jun 13;4(138):138ra81. doi: 10.1126/scitranslmed.3003876.
2
Ebola GP-specific monoclonal antibodies protect mice and guinea pigs from lethal Ebola virus infection.埃博拉糖蛋白特异性单克隆抗体可保护小鼠和豚鼠免受致命性埃博拉病毒感染。
PLoS Negl Trop Dis. 2012;6(3):e1575. doi: 10.1371/journal.pntd.0001575. Epub 2012 Mar 20.
3
Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease.接触后抗体预防可保护非人灵长类动物免受丝状病毒病的侵害。
Proc Natl Acad Sci U S A. 2012 Mar 27;109(13):5034-9. doi: 10.1073/pnas.1200409109. Epub 2012 Mar 12.
4
Characterization of Zaire ebolavirus glycoprotein-specific monoclonal antibodies.扎伊尔埃博拉病毒糖蛋白特异性单克隆抗体的鉴定。
Clin Immunol. 2011 Nov;141(2):218-27. doi: 10.1016/j.clim.2011.08.008. Epub 2011 Aug 31.
5
CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates.CD8+ 细胞免疫介导 rAd5 疫苗对非人灵长类动物埃博拉病毒感染的保护作用。
Nat Med. 2011 Aug 21;17(9):1128-31. doi: 10.1038/nm.2447.
6
Human fatal zaire ebola virus infection is associated with an aberrant innate immunity and with massive lymphocyte apoptosis.人类致命扎伊尔埃博拉病毒感染与异常的先天免疫和大量淋巴细胞凋亡有关。
PLoS Negl Trop Dis. 2010 Oct 5;4(10):e837. doi: 10.1371/journal.pntd.0000837.
7
Enzyme-linked immunosorbent assay for detection of filovirus species-specific antibodies.用于检测丝状病毒属特异性抗体的酶联免疫吸附测定。
Clin Vaccine Immunol. 2010 Nov;17(11):1723-8. doi: 10.1128/CVI.00170-10. Epub 2010 Sep 22.
8
Correlates of protection induced by vaccination.疫苗接种诱导的保护相关性。
Clin Vaccine Immunol. 2010 Jul;17(7):1055-65. doi: 10.1128/CVI.00131-10. Epub 2010 May 12.
9
Mucosal immunization of cynomolgus macaques with the VSVDeltaG/ZEBOVGP vaccine stimulates strong ebola GP-specific immune responses.用VSVDeltaG/ZEBOVGP疫苗对食蟹猴进行黏膜免疫可刺激强烈的埃博拉病毒糖蛋白特异性免疫反应。
PLoS One. 2009;4(5):e5547. doi: 10.1371/journal.pone.0005547. Epub 2009 May 14.
10
Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus.单次注射疫苗可保护非人灵长类动物免受马尔堡病毒和三种埃博拉病毒的感染。
J Virol. 2009 Jul;83(14):7296-304. doi: 10.1128/JVI.00561-09. Epub 2009 Apr 22.
Zotero 插件